Amivantamab, a bispecific antibody targeting both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET), has demonstrated robust and durable clinical activity in patients with EGFR exon 20 insertion-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.